Importantly, CaMKII is well established as a central mediator for forms of synaptic plasticity thought to underlie cognition (Bayer and Schulman, 2019), further enhancing plausibility of CaMKII, a pharmacological target for restoring this major unmet need in schizophrenia therapy. The gene discussed is CAMK2G; the disease is schizophrenia.